Paris Panayiotopoulos

Paris Panayiotopoulos is a seasoned entrepreneur and board director, currently serving as the Founder and Board Director at Anthos Therapeutics and AvenCell. They have held significant roles in various companies, including Partner at Clarus Funds, which was sold to Blackstone in 2018, and CEO at ARIAD Pharmaceuticals, which was sold to Takeda in 2017. Paris has also contributed as a Board Director at The Medicines Company prior to its acquisition by Novartis in 2020, and was involved in leadership roles at Merck KGaA in Japan and North America. Their career spans several leadership positions across the healthcare and biotechnology sectors, showcasing a strong commitment to innovation and strategy.